Salvianolic Acid A Mitigates Osteoporotic Bone Loss by Repressing Reactive Oxygen Species via the Nrf2–HO‐1 Pathway
Phytotherapy Research · 2025
DOI: 10.1002/ptr.8503 ↗At a glance
Journal article in Phytotherapy Research, 2025. Written by Hao Qiu and 5 co-authors. Institution: Department of Orthopedics, Xinqiao Hospital, Army Medical University, Chongqing, China. Major MEDLINE topics: NF-E2-Related Factor 2, Reactive Oxygen Species, Osteoporosis, Caffeic Acids. Cited 8 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY 4.0). Funded by: the Clinical Research Project of the Second Affiliated Hospital of Army Medical University, the Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission.
Abstract (original language)
Osteoporosis, characterized by osteoclastic bone resorption, has been the focus of research. Studies implicate that reactive oxygen species (ROS) accumulate intracellularly during osteoclastogenesis. Salvianolic acid A (SAA), a compound derived from Salvia miltiorrhiza , has been widely used to treat cardiovascular and cerebrovascular disorders, owing to its antioxidant and anti‐inflammatory properties. In this study, we investigated the therapeutic effects of SAA on osteoporotic bone loss in vitro and in osteoporotic mice induced by ovariectomy (OVX) and explored the underpinning mechanisms. In vitro, SAA significantly restrained osteoclastogenesis and osteoclastic resorption in a dose‐ and time‐dependent manner. SAA markedly blocked the expression of osteoclast‐specific genes and proteins such as NFATc1 and c‐Fos. Specifically, SAA reduced ROS production by enhancing the expression and nuclear translocation of nuclear factor erythroid 2‐related factor 2 (Nrf2) to activate HO‐1 and catalase, with no effect on Bach1. In addition, SAA simultaneously suppressed the NF‐κB and mitogen‐activated protein kinase (MAPK) signaling pathway, ultimately arresting NFATc1 expression to constrain the differentiation and function of osteoclasts. Micro‐CT and histological evidence demonstrated that SAA at a nontoxic dose successfully reduced bone loss induced by OVX, with fewer mature osteoclasts. These findings revealed that SAA provides a potential treatment strategy for reducing osteoclast‐related bone ailments, including osteoporosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Orthopedics, Xinqiao Hospital, Army Medical University, Chongqing, China.
ORCID profiles: Hao Qiu
Funding
- the Clinical Research Project of the Second Affiliated Hospital of Army Medical University
- the Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission
Cite
APA
Qiu, H., Cai, C., Zhang, Y., Yang, S., Hu, X., & Chu, T. (2025). Salvianolic Acid A Mitigates Osteoporotic Bone Loss by Repressing Reactive Oxygen Species via the Nrf2–HO‐1 Pathway. Phytotherapy Research. https://doi.org/10.1002/ptr.8503
Vancouver
Qiu H, Cai C, Zhang Y, Yang S, Hu X, Chu T. Salvianolic Acid A Mitigates Osteoporotic Bone Loss by Repressing Reactive Oxygen Species via the Nrf2–HO‐1 Pathway. Phytotherapy Research. 2025. doi:10.1002/ptr.8503
BibTeX
@article{Qiu2025,
author = {Qiu, Hao and Cai, Chenhui and Zhang, Ying and Yang, Sizhen and Hu, Xu and Chu, Tongwei},
title = {Salvianolic Acid A Mitigates Osteoporotic Bone Loss by Repressing Reactive Oxygen Species via the Nrf2–HO‐1 Pathway},
journal = {Phytotherapy Research},
year = {2025},
doi = {10.1002/ptr.8503}
}
EUVIMED